Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Gilead Moves On From Selonsertib, Looks To ATLAS To Map Its NASH Future

Gilead, Liver Meeting stage — Gilead presents the full Phase III dataset for selonsertib at AASLD 2019

Related Content

Intercept Says Data Indicate Pruritus Worries In NASH Could Be Overstated

Nov 11 2019

Gilead Hit With Another NASH Setback As Selonsertib Fails In First Phase III

Feb 11 2019

Gilead Increasingly Seems Focused On Combo Therapy In NASH

Apr 12 2019

Related Companies

Gilead Sciences, Inc.

Intercept Pharmaceuticals, Inc.

Novo Nordisk A/S

Additional Topics

Clinical Trials Business Strategies Research & Development Liver & Hepatic BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window